SNOA
Sonoma Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$1.12
+0.00%Year over year
Reported trailing growth
- Revenue
- +47.0%
- EBITDA
- +53.9%
- EBIT
- +61.3%
- EPS
- +53.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -49.0%
- EBITDA
- +85.4%
- EPS
- +93.4%
Three-year CAGR
- Revenue
- +13.7%
- EBITDA
- +16.1%
- EBIT
- +33.7%
- Net income
- +8.2%
- EPS
- +32.3%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026